Skip to main content About Us Pipeline Our Companies For Investors Join Us By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation and analyze site usage. This site uses cookies as described in our Privacy Policy and Terms of Use. Customize Settings Reject Accept All Pipeline We have a broad and differentiated pipeline of investigational drugs across our family of companies. 10 Phase 3 clinical trials (9 of which have been successful) We have run numerous large successful international Phase 3 clinical trials. Agnostic to therapeutic area and modality Our pipeline includes innovative product candidates across numerous therapeutic areas including immunology, oncology, hematology, and dermatology. Filter             All                                                                          Affivant                                             Dermavant                                             Hemavant                                             Immunovant                                             Kinevant                                             New Vant                                             Priovant                                                                                                                           Preclinical                                             Phase 1                                             Phase 2                                             Phase 3                                             Commercialization                                                           Topical · Dermavant VTAMA (Tapinarof) Psoriasis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Topical · Dermavant VTAMA (Tapinarof) Atopic Dermatitis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant Batoclimab Myasthenia Gravis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant Batoclimab Thyroid Eye Disease Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant Batoclimab WAIHA Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant Batoclimab CIDP Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant Batoclimab Graves' Disease Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Immunovant IMVT-1402 Numerous Indications Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Small Molecule · Priovant Brepocitinib Dermatomyositis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Small Molecule · Priovant Brepocitinib Systemic Lupus Erythematosus Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Small Molecule · Priovant Brepocitinib Other Indications Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · New Vant RVT-3101 Ulcerative Colitis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · New Vant RVT-3101 Crohn's Disease Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Kinevant Namilumab Sarcoidosis Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Small Molecule · Hemavant RVT-2001 Transfusion Dependent Anemia in Patients with Lower-Risk MDs Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Biologic · Affivant AFVT-2101 Solid Tumors Preclinical Phase 1 Phase 2 Phase 3 Review Commercialization Interested in learning more? Discover how our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.  Read more Nimble, entrepreneurial Vants Explore our diverse family of biopharmaceutical and health technology companies.  Read more Interested in Joining Us? Join the team changing the future of healthcare. A career at Roivant is filled with remarkable growth opportunities for those tackling the most significant challenges in science and technology. See available positions About Us Pipeline Our Companies Join Us Contact Us New York 151 W 42nd Street 15th Floor New York, NY 10036 United States Boston 451 D Street Boston, MA 02210 United States Basel Viaduktstrasse 8 4051 Basel Switzerland © 2023 Roivant Sciences Ltd. All Rights Reserved Privacy policy Terms of use Legal